FDA Approves Second Over-the-Counter Naloxone Nasal Spray Product

At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing. RiVive is a nonprescription product for the emergency treatment of a known or suspected opioid overdose.